Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:14 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Recruiting Phase 1 Interventional

Trial of Cell Based Therapy for DMD

NCT06692426
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
MyoPAXon, Tacrolimus
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 2, 2026, 2:14 AM EST
Completed Not applicable Interventional

Lung Cancer Informational Study (LCIS)

NCT00579215
View directory record Official record
Conditions
Cancer, Enhanced Care, Decision-Making, Advance Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Enhance Care, Usual Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Nov 2, 2026, 2:14 AM EST
Completed Not applicable Interventional

Early Staged Consent Before Prostate Biopsy

NCT03507725
View directory record Official record
Conditions
Prostate Cancer
Interventions
Meditation, Prostate Biopsy, Questionnaires
Behavioral · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 2, 2026, 2:14 AM EST
Terminated Phase 1 Interventional Results available

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03197025
View directory record Official record
Conditions
Human Papillomavirus, HPV-16, High Grade Squamous Intraepithelial Lesion
Interventions
Aldesleukin, E6 T Cell Receptor (TCR)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Nov 2, 2026, 2:14 AM EST
Terminated Phase 2 Interventional Results available

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04437368
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Nov 2, 2026, 2:14 AM EST
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses

NCT00570843
View directory record Official record
Conditions
Comfort, Vision and Wear Time
Interventions
New PEG based artificial tear, Optive
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Nov 2, 2026, 2:14 AM EST
Completed Not applicable Interventional

Helping Individuals With Firearm Injuries

NCT02630225
View directory record Official record
Conditions
Wounds, Gunshot
Interventions
Critical Time Intervention, Treatment as Usual, Motivational Interviewing, Multi-Agency Attention
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Nov 2, 2026, 2:14 AM EST
Completed Not applicable Interventional Results available

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine

NCT00293293
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
Interventions
healing touch, massage therapy, hypnosis, Standard chemotherapy
Other · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Nov 2, 2026, 2:14 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness

NCT05880004
View directory record Official record
Conditions
Improving Healthy Food Access in Food Insecurity Populations in Normal and Emergency Situations
Interventions
Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 4 Interventional Results available

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

NCT02995915
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring
Other · Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Nov 2, 2026, 2:14 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

NCT03287817
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
AUTO3
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Nov 2, 2026, 2:14 AM EST
Active, not recruiting Phase 2 Interventional

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

NCT01512589
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Proton Beam Therapy (PBT), Intensity Modulated Radiation Therapy (IMRT), Questionnaires
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 2, 2026, 2:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Sleep Restriction on BAT Activation in Humans

NCT02770118
View directory record Official record
Conditions
Sleep Deprivation, Obesity
Interventions
Partial Sleep Restriction, Total Sleep Deprivation, Habitual Sleep
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 49 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 2 Interventional Results available

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

NCT00803647
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
cetuximab, 5-FU, oxaliplatin, leucovorin
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Loma Linda, California • Orange, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Nov 2, 2026, 2:14 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects

NCT01029015
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry, polysomnography
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 2, 2026, 2:14 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions
HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
Drug
Lead sponsor
Hemab ApS
Industry
Eligibility
16 Years to 69 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 2, 2026, 2:14 AM EST
Completed Not applicable Interventional Results available

Healing Hearts and Mending Minds in Older Adults Living With HIV

NCT02711878
View directory record Official record
Conditions
HIV, Cardiovascular Disease, AIDS
Interventions
Let's Move Program, Let's Flex Program, Group Motivational Interviewing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
40 Years to 89 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Nov 2, 2026, 2:14 AM EST
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

NCT03753243
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide
Drug
Lead sponsor
Mark Garzotto, MD
Federal
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C

NCT03471143
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
VTS-270
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 6 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

NCT02151617
View directory record Official record
Conditions
Healthy
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Nov 2, 2026, 2:14 AM EST
Terminated Phase 1Phase 2 Interventional

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

NCT01929954
View directory record Official record
Conditions
Edentulous Alveolar Ridge
Interventions
Gintuit, Bio-Gide
Biological · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Nov 2, 2026, 2:14 AM EST
Completed Phase 3 Interventional Results available

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066
View directory record Official record
Conditions
Myasthenic Syndromes, Congenital
Interventions
amifampridine phosphate, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 2, 2026, 2:14 AM EST